Keytruda 100 MG/4 ML vial 4ML
Ended Awarded Last action
- Contract number
- SPE2DR26FKKG7
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $83,729
Award facts
- Contract value 100% obligated
- $83,728.70 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $83,728.70 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Keytruda 100 mg/4 mL vials. The award, issued on December 16, 2025, with an ultimate completion date of January 8, 2026, carries no set-aside designation, demonstrating the vendor's competitive capability in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a single-award contract valued at $499,999,999 that was awarded on November 13, 2025, and runs through December 31, 2036.
As a critical supplier within the federal pharmaceutical supply chain, DMS Pharmaceutical Group supplies a comprehensive portfolio of pharmaceuticals and medical consumables to Department of Defense healthcare facilities worldwide. The PPV-G GEN V program represents a $30.3 billion acquisition strategy designed to establish multiple regional prime vendor contractors capable of fulfilling diverse and specialized pharmaceutical requirements for military healthcare operations globally. This delivery order for Keytruda, a branded oncology treatment, exemplifies the company's role in supporting the specialized pharmaceutical needs of the federal military medical system with no identified subcontractors involved in contract performance.
Quick answers
Who was awarded contract SPE2DR26FKKG7?
SPE2DR26FKKG7 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 16, 2025.
How much is contract SPE2DR26FKKG7 worth?
The government has obligated $83,729 on SPE2DR26FKKG7.
Is contract SPE2DR26FKKG7 an order under another contract?
Yes. SPE2DR26FKKG7 is a delivery order under SPE2DR25D9367, an indefinite delivery contract.
Was contract SPE2DR26FKKG7 competed?
The extent of competition for SPE2DR26FKKG7 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award